Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 47,963 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 47,963 shares of the company’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $0.72, for a total transaction of $34,533.36. Following the sale, the director directly owned 1,679,330 shares in the company, valued at $1,209,117.60. This represents a 2.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total transaction of $42,627.62.
• On Thursday, April 30th, Luke Evnin sold 168,262 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total transaction of $121,148.64.
• On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total transaction of $39,025.71.
• On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total transaction of $69,650.76.
• On Monday, April 27th, Luke Evnin sold 53,940 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.85, for a total transaction of $45,849.00.

Werewolf Therapeutics Price Performance

HOWL opened at $0.69 on Tuesday. Werewolf Therapeutics, Inc. has a one year low of $0.53 and a one year high of $2.38. The company’s 50 day simple moving average is $0.81 and its 200-day simple moving average is $0.88. The stock has a market capitalization of $33.53 million, a P/E ratio of -0.51 and a beta of 0.41.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Friday, March 27th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.14. As a group, analysts anticipate that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on HOWL shares. Wall Street Zen raised shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, April 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $3.75.

Institutional Investors Weigh In On Werewolf Therapeutics

Several hedge funds have recently bought and sold shares of HOWL. Regal Investment Advisors LLC raised its holdings in Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares during the period. Vontobel Holding Ltd. raised its holdings in Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after purchasing an additional 24,003 shares during the period. Qube Research & Technologies Ltd acquired a new stake in Werewolf Therapeutics in the second quarter worth $48,000. AQR Capital Management LLC acquired a new stake in Werewolf Therapeutics in the first quarter worth $79,000. Finally, Bridgeway Capital Management LLC raised its holdings in Werewolf Therapeutics by 157.7% in the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after purchasing an additional 62,414 shares during the period. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.